TheAesthetic Index

Cutera Pearl / Pearl Fractional

Er:YSGG Resurfacing · 2790nm YSGG ablative (xeo handpieces)

Work at Cutera? — one claim covers all 19 of your devices.
Legacy-used-marketBe the first to review

New Cutera Pearl / Pearl Fractional pricing is not published; used and refurbished systems trade around $10k–$25k. Cutera Pearl / Pearl Fractional's FDA status is under verification by our research team. Figures are market estimates verified August 9, 2026.

What it's actually cleared for: 2790nm YSGG superficial ablative resurfacing; cleared 2007 per Cutera filings — K not located

Last verified: August 9, 2026 · How we verify

New: —|Used: $10k–$25kmarket estimate, no email required

Key facts
ManufacturerCutera
CompanyOwner: Private; held by former lenders following Chapter 11 restructuring (private equity owned, since 2025) · Distribution: direct
CategoryResurfacing, Tattoo & Vascular
Technology2790nm YSGG ablative (xeo handpieces)
FDA statusCleared — citation pending verification
New price rangeNot published
Used price range$10k–$25k
ConsumablesNot published
Launch year2007
Last verifiedAugust 9, 2026
Save device

Overview

Pearl peel middle-ground resurfacing, now legacy

FDA & regulatory status

Citation pending verification

Clearance is expected for this platform, but we have not yet confirmed the exact authorization number against the public FDA database, so no number is published here. See our FDA guide.

What it's actually cleared for:

2790nm YSGG superficial ablative resurfacing; cleared 2007 per Cutera filings — K not located

Regulatory data is compiled from public FDA 510(k) records and may lag recent clearances. Always confirm status with the manufacturer before purchase.

Recent industry events

How we source company data

Ownership and corporate changes at Cutera that can affect warranty, service and parts availability.

  1. Mar 2025

    Cutera files Chapter 11 and emerges private

    Bankruptcy
    Service & warranty risk

    Cutera filed for Chapter 11 bankruptcy protection on March 5-6, 2025 and was delisted from NASDAQ that month. It emerged from bankruptcy on May 1, 2025 as a private company held by its former lenders, cutting debt by ~$400M (over 90%) and raising $65M of new capital. Buyers should confirm current warranty, service and parts commitments directly.

    Source: SEC filings; Lexology; The D&O Diary

Treatment economics

Economics data for this platform hasn't been published yet.

Chains using this device

No confirmed chain deployments recorded yet.

Owner reviews

Write a review

No verified reviews yet — be the first. Founding reviewers get a thank-you gift card for an honest review, positive or negative. How verification works.

Alternatives

Cutera AviClear

Acne laser (1726nm sebaceous) · $100k–$150k

ProfileCompare

Iridex DioLite XP

KTP/532 & Nd:YAG Vascular

ProfileCompare

DEKA (Cartessa) SmartXide Punto

CO2 Fractional/Ablative · $60k–$90k

ProfileCompare

Lumenis AcuPulse DUO

CO2 Fractional/Ablative · $100k–$140k

ProfileCompare

History

Every tracked change to pricing, lifecycle status, FDA data and warranty terms — newest first.

  1. August 9, 2026

    FDA status

    Cleared → Cleared-Pending-Citation

    Source: Automatic record update

  2. August 1, 2026

    Record created

    Added to The Aesthetic Index — August 2026

    Source: The Aesthetic Index editorial

Get the full State of Aesthetic Devices 2026 report

The first full census of the US aesthetic device market — preview it free.

Get the report